Antibody NI006 for treatment of transthyretin amyloid cardiomyopathy caused no serious adverse events
1. In this randomized controlled trial, the antibody NI006 for the treatment of transthyretin amyloid cardiomyopathy (ATTR) showed no associated drug-related ...